Prophylactic Treatment Protocol against the Severity of COVID-19 Using Melatonin
Charaa et al.
, Prophylactic Treatment Protocol against the Severity of COVID-19 Using Melatonin
, SSRN, doi:10.2139/ssrn.3601861 (Review) (Preprint)
Review of the potential benefits of melatonin for COVID-19, and a proposed prophylactic treatment protocol.
Charaa et al., 4 May 2020, preprint, 4 authors.
Abstract: May 4, 2020
Prophylactic treatment protocol against the severity
of COVID-19 using melatonin
Dr Nejib CHARAA1 *, Pr Mohamed CHAHED2 , Pr Habib GHEDIRA 3 , Pr Riadh DAGHFOUS4
The Corona Virus Disease 2019 (COVID-19) pandemic reached more than 150 countries in all continent in two
months, after triggering in Wuhan, China in late December 2019. One of the main features of this pandemic is
the increased severity of the disease with age and the highest proportion of serious cases among males. Most
severe cases were caused by an intensive immune response with massive release of cytokines which induces
acute respiratory distress syndrome and multi-visceral failure. Melatonin is the major neuro-hormone secreted
by the pineal gland. The synthesis of this hormone shows a circadian pattern. Melatonin secretion gradually
decreases with age and becomes clear in people over the age of 60. This deprivation is inversely proportional
to the increase in mortality due to COVID-19 with age. Also the level of this hormone seems to be higher in
women. It is assumed that melatonin with its immunomodulatory and antiviral actions plays a protective role
against the severity of SARS-CoV-2 infection. Following our review, we concluded that this hypothesis was highly
plausible and we proposed a prophylactic treatment protocol against the severity of COVID-19 using a melatonin
COVID-19 — SARS-CoV-2 — Coronavirus — Melatonin — Prophylaxis — Treatment
Health Director. Regional Health Directorate of Kebili, Tunisia
of Epidemiology and Public Health, Faculty of Medicine of Tunis, Tunis-El Manar University, Tunis, Tunisia
3 Head of Pulmonary Diseases Dpt I - A. Mami Chest Diseases Hospital, Ariana 2080, Tunisia
4 National Center of Pharmacovigilance General Director. University of Tunis El Manar Department of Basic Sciences B, Tunisia.
*Corresponding author: firstname.lastname@example.org
Please send us corrections, updates, or comments. Vaccines and
treatments are complementary. All practical, effective, and safe means should
be used based on risk/benefit analysis. No treatment, vaccine, or intervention
is 100% available and effective for all current and future variants. We do not
provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation. FLCCC
provide treatment protocols.